Form 4: BioMarin CTO Reports Equity Transactions

BioMarin Pharmaceutical's EVP and Chief Technical Officer, Charles Greg Guyer, reported the acquisition of restricted stock units and stock options, alongside a disposition of common stock for tax purposes.

Summary

• Charles Greg Guyer, EVP, Chief Technical Officer of BioMarin Pharmaceutical Inc. (BMRN), reported changes in his beneficial ownership of company securities.
• On March 13, 2026, Guyer disposed of 9,109 shares of common stock at a price of $58.51 per share, likely for tax withholding purposes related to vesting.
• Following this disposition, his direct beneficial ownership of common stock was 70,843 shares, adjusted by one share to correct a previous clerical error.
• On March 16, 2026, Guyer acquired 14,990 shares of common stock in the form of restricted stock units (RSUs) at a price of $0, as these are grants.
• Also on March 16, 2026, Guyer was granted 35,680 stock options with an exercise price of $57.43 per share.
• After these transactions, Guyer's direct beneficial ownership of common stock increased to 85,833 shares, and he holds 35,680 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting ongoing executive compensation and alignment of interests, which is a standard and generally healthy sign for corporate governance, though not indicative of new operational performance.

Positives

• The acquisition of 14,990 restricted stock units (RSUs) on March 16, 2026, represents a grant of equity compensation to the executive.
• The grant of 35,680 stock options on March 16, 2026, further aligns the executive's interests with shareholder value creation.

Negatives

• The disposition of 9,109 shares of common stock on March 13, 2026, reduces the executive's direct equity holdings, although this is a common practice for tax withholding upon RSU vesting.

Future Outlook

The stock options granted on March 16, 2026, will vest 12/48th on March 16, 2027, and 1/48th on the 16th day of each month thereafter, with an expiration date of March 15, 2036.

Industry Context

StockSavvy.ai notes that these transactions reflect routine executive compensation practices within the biotechnology and pharmaceutical industry, where equity grants like restricted stock units and stock options are standard components of long-term incentive plans designed to align executive interests with shareholder returns.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity compensation, involving both restricted stock units and stock options with a multi-year vesting schedule, is consistent with common practices among peer companies in the biopharmaceutical sector, such as Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX), which frequently utilize similar mechanisms to incentivize and retain key executives.
• The disposition of shares for tax withholding purposes is a standard and expected event when restricted stock units vest, aligning with typical tax implications for equity compensation across publicly traded companies.

Stakeholder Impact

• Shareholders: The grant of equity compensation to a key executive aims to align management's long-term interests with shareholder value, potentially fostering sustained performance.
• Employees: These transactions are specific to a senior executive and do not directly impact the broader employee base, though they reflect the company's overall compensation philosophy for leadership.

Next Steps

• The stock options granted on March 16, 2026, will begin vesting on March 16, 2027, with subsequent monthly vesting until fully vested.

Key Dates

Keywords

BMRN, BioMarin Pharmaceutical, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership